Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Aortic valve disease in the older adult.

Bhatia N, Basra SS, Skolnick AH, Wenger NK.

J Geriatr Cardiol. 2016 Dec;13(12):941-944. doi: 10.11909/j.issn.1671-5411.2016.12.004. No abstract available.

2.

Deficiency in the anti-aging gene Klotho promotes aortic valve fibrosis through AMPKα-mediated activation of RUNX2.

Chen J, Lin Y, Sun Z.

Aging Cell. 2016 Oct;15(5):853-60. doi: 10.1111/acel.12494. Epub 2016 May 31.

3.

The effect of statins therapy in aortic stenosis: Meta-analysis comparison data of RCTs and observationals.

Zhao Y, Nicoll R, He YH, Henein MY.

Data Brief. 2016 Feb 26;7:357-61. doi: 10.1016/j.dib.2016.02.045. eCollection 2016 Jun.

4.

Involvement of Immune Cell Network in Aortic Valve Stenosis: Communication between Valvular Interstitial Cells and Immune Cells.

Lee SH, Choi JH.

Immune Netw. 2016 Feb;16(1):26-32. doi: 10.4110/in.2016.16.1.26. Epub 2016 Feb 25. Review.

5.

Calcific Aortic Valve Disease: Part 1--Molecular Pathogenetic Aspects, Hemodynamics, and Adaptive Feedbacks.

Pasipoularides A.

J Cardiovasc Transl Res. 2016 Apr;9(2):102-18. doi: 10.1007/s12265-016-9679-z. Epub 2016 Feb 18. Review.

6.

Simvastatin Attenuates Oxidative Stress, NF-κB Activation, and Artery Calcification in LDLR-/- Mice Fed with High Fat Diet via Down-regulation of Tumor Necrosis Factor-α and TNF Receptor 1.

Lin CP, Huang PH, Lai CF, Chen JW, Lin SJ, Chen JS.

PLoS One. 2015 Dec 1;10(12):e0143686. doi: 10.1371/journal.pone.0143686. eCollection 2015. Erratum in: PLoS One. 2016;11(1):e0148590.

7.

Drug Therapy for Heart Valve Diseases.

Borer JS, Sharma A.

Circulation. 2015 Sep 15;132(11):1038-45. doi: 10.1161/CIRCULATIONAHA.115.016006. Review. No abstract available.

8.

A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial).

Bull S, Loudon M, Francis JM, Joseph J, Gerry S, Karamitsos TD, Prendergast BD, Banning AP, Neubauer S, Myerson SG.

Eur Heart J Cardiovasc Imaging. 2015 Aug;16(8):834-41. doi: 10.1093/ehjci/jev043. Epub 2015 Mar 21.

9.

Effect of study design on the reported effect of cardiac resynchronization therapy (CRT) on quantitative physiological measures: stratified meta-analysis in narrow-QRS heart failure and implications for planning future studies.

Jabbour RJ, Shun-Shin MJ, Finegold JA, Afzal Sohaib SM, Cook C, Nijjer SS, Whinnett ZI, Manisty CH, Brugada J, Francis DP.

J Am Heart Assoc. 2015 Jan 6;4(1):e000896. doi: 10.1161/JAHA.114.000896. Review.

10.

Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis.

Smith JG, Luk K, Schulz CA, Engert JC, Do R, Hindy G, Rukh G, Dufresne L, Almgren P, Owens DS, Harris TB, Peloso GM, Kerr KF, Wong Q, Smith AV, Budoff MJ, Rotter JI, Cupples LA, Rich S, Kathiresan S, Orho-Melander M, Gudnason V, O'Donnell CJ, Post WS, Thanassoulis G; Cohorts for Heart and Aging Research in Genetic Epidemiology (CHARGE) Extracoronary Calcium Working Group..

JAMA. 2014 Nov 5;312(17):1764-71. doi: 10.1001/jama.2014.13959.

11.

Insights into aortic sclerosis and its relationship with coronary artery disease.

Milin AC, Vorobiof G, Aksoy O, Ardehali R.

J Am Heart Assoc. 2014 Sep 5;3(5):e001111. doi: 10.1161/JAHA.114.001111. Review. No abstract available.

12.

Current management of calcific aortic stenosis.

Lindman BR, Bonow RO, Otto CM.

Circ Res. 2013 Jul 5;113(2):223-37. doi: 10.1161/CIRCRESAHA.111.300084. Review.

13.

Degenerative valve disease and bioprostheses: risk assessment, predictive diagnosis, personalised treatments.

Yeghiazaryan K, Skowasch D, Bauriedel G, Schild HH, Golubnitschaja O.

EPMA J. 2011 Mar;2(1):91-105. doi: 10.1007/s13167-011-0072-3. Epub 2011 Apr 3.

14.

The effect of angiotensin-converting enzyme inhibitors and statins on the progression of aortic sclerosis and mortality.

Ardehali R, Leeper NJ, Wilson AM, Heidenreich PA.

J Heart Valve Dis. 2012 May;21(3):337-43.

15.
16.

Pathogenesis of aortic stenosis: not just a matter of wear and tear.

Sverdlov AL, Ngo DT, Chapman MJ, Ali OA, Chirkov YY, Horowitz JD.

Am J Cardiovasc Dis. 2011;1(2):185-99. Epub 2011 Jul 28.

17.

Predictors of echocardiographic progression in patients with mild aortic stenosis.

Seo JS, Kang DH, Kim DH, Song JM, Song JK.

Korean Circ J. 2011 Nov;41(11):649-53. doi: 10.4070/kcj.2011.41.11.649. Epub 2011 Nov 29.

18.

The pathophysiological basis of pharmacological interventions in CAVD.

Riem Vis PW, van Rijswijk JW, Chamuleau SA, Vink A, van Herwerden LA, Kluin J.

Neth Heart J. 2012 Jun;20(6):270-8. doi: 10.1007/s12471-011-0230-1.

19.

Animal models of calcific aortic valve disease.

Sider KL, Blaser MC, Simmons CA.

Int J Inflam. 2011;2011:364310. doi: 10.4061/2011/364310. Epub 2011 Aug 2.

20.

Calcific aortic valve stenosis: methods, models, and mechanisms.

Miller JD, Weiss RM, Heistad DD.

Circ Res. 2011 May 27;108(11):1392-412. doi: 10.1161/CIRCRESAHA.110.234138. Review.

Supplemental Content

Support Center